Kadimastem Stock Performance
| KMSTF Stock | USD 2.63 0.10 3.95% |
The company secures a Beta (Market Risk) of 0.12, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kadimastem's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kadimastem is expected to be smaller as well. At this point, Kadimastem has a negative expected return of -1.29%. Please make sure to verify Kadimastem's treynor ratio, as well as the relationship between the kurtosis and day typical price , to decide if Kadimastem performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Kadimastem has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 5.4 M | |
| Total Cashflows From Investing Activities | -380 K |
Kadimastem |
Kadimastem Relative Risk vs. Return Landscape
If you would invest 717.00 in Kadimastem on September 28, 2025 and sell it today you would lose (454.00) from holding Kadimastem or give up 63.32% of portfolio value over 90 days. Kadimastem is currently producing negative expected returns and takes up 7.4219% volatility of returns over 90 trading days. Put another way, 66% of traded pink sheets are less volatile than Kadimastem, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Kadimastem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kadimastem's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Kadimastem, and traders can use it to determine the average amount a Kadimastem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1735
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KMSTF |
Based on monthly moving average Kadimastem is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kadimastem by adding Kadimastem to a well-diversified portfolio.
Kadimastem Fundamentals Growth
Kadimastem Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Kadimastem, and Kadimastem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kadimastem Pink Sheet performance.
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 10.09 M | |||
| Shares Outstanding | 35.76 M | |||
| Price To Book | 5.03 X | |||
| EBITDA | (24.48 M) | |||
| Cash And Equivalents | 250 K | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 9.31 M | |||
| Debt To Equity | 0.39 % | |||
| Cash Flow From Operations | (21.55 M) | |||
| Total Asset | 27.34 M | |||
About Kadimastem Performance
By analyzing Kadimastem's fundamental ratios, stakeholders can gain valuable insights into Kadimastem's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kadimastem has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kadimastem has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. Kadimastem operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Kadimastem performance evaluation
Checking the ongoing alerts about Kadimastem for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Kadimastem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kadimastem generated a negative expected return over the last 90 days | |
| Kadimastem has high historical volatility and very poor performance | |
| Kadimastem has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (26.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kadimastem has accumulated about 250 K in cash with (21.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 54.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Kadimastem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kadimastem's stock is overvalued or undervalued compared to its peers.
- Examining Kadimastem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kadimastem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kadimastem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kadimastem's pink sheet. These opinions can provide insight into Kadimastem's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kadimastem Pink Sheet analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |